Patient Testimonials

Fran's Story: Expanded Access Program Patient

Fran’s personal experience began in 1996, when her mother was diagnosed with acral lentiginous melanoma , which eventually took her life.  In 2017, Fran found a small red dot on her foot and immediately knew what it was – melanoma.

Fran received surgery, radiation, nivolumab, ipilimumab, pembrolizumab and T-VEC but the melanoma still spread throughout her body – including her lung, liver, chest cavity, neck and brain.

Fran then learned about TAVO™ (tavokinogene telseplasmid) from her oncologist and got access to treatment through the Expanded Access Program.

Watch Fran’s story to learn how she got off the one way street with a dead end.

Sharon's Story: KEYNOTE-695 Patient

Sharon’s personal journey with cancer began three years ago when she was diagnosed with melanoma. She had no family history of melanoma and was shocked when her doctor told her a mark under her fingernail was actually acral melanoma. She immediately had surgery to remove part of her finger but the cancer still spread up her arm.

Sharon then underwent a cycle of treatments, including checkpoint therapy, that came with side-effects and failed to stop her cancer from spreading. Finally, when Sharon’s cancer had spread to over 50 melanomas, her doctor recommended she enroll in the ongoing KEYNOTE-695 clinical trial evaluating TAVO in combination with KEYTRUDA® (pembrolizumab).

Hear Sharon’s story how she found her “saving grace” and “got her life back” after TAVO treatment.

Julie's Story: KEYNOTE-890 Patient

When Julie was diagnosed with triple negative breast cancer (TNBC) she didn’t understand exactly what that meant. She went home to do more research and quickly learned that TNBC was the most aggressive type of breast cancer with poorer prognosis because it lacks all three types of receptors that targeted medicines need to effectively treat the cancer. Thus, the primary treatment for TNBC remains chemotherapy.

Julie started chemotherapy treatment but it came at a high cost and the side-effects were debilitating. Ultimately chemotherapy didn’t work for Julie and she found herself “wondering where to go from here.” She describes it as the worst day of her life.

Then Julie learned about TAVO from her doctor and enrolled in the ongoing KEYNOTE-890 clinical trial.

Julie tells her story of an “emotional rollercoaster ride” and “finding hope again” after being diagnosed with TNBC.

OncoSec’s product candidates are investigational and have not been approved by the FDA. The results described in the testimonials may not be representative of the patient experience as the product candidates remain investigational.